Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

DECIPHERA PHARMACEUTICALS, INC.

(DCPH)
  Report
Delayed Nasdaq  -  04:00 2022-10-05 pm EDT
18.94 USD   -0.53%
09/27Stifel Adjusts Price Target on Deciphera Pharmaceuticals to $18 From $11, Reiterates Hold Rating
MT
09/12Piper Sandler Raises Deciphera Pharmaceuticals Price Target to $18 From $13, Maintains Neutral Rating
MT
09/12SVB Securities Adjusts Deciphera Pharmaceuticals' Price Target to $25 from $21, Maintains Outperform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Deciphera Pharmaceuticals' Q2 Loss Narrows, Revenue Rises

08/04/2022 | 12:26pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
DECIPHERA PHARMACEUTICALS, INC. -0.53% 18.94 Delayed Quote.94.88%
NOVARTIS AG -0.81% 76.35 Delayed Quote.-4.12%
All news about DECIPHERA PHARMACEUTICALS, INC.
09/27Stifel Adjusts Price Target on Deciphera Pharmaceuticals to $18 From $11, Reiterates Ho..
MT
09/12Piper Sandler Raises Deciphera Pharmaceuticals Price Target to $18 From $13, Maintains ..
MT
09/12SVB Securities Adjusts Deciphera Pharmaceuticals' Price Target to $25 from $21, Maintai..
MT
09/12HC Wainwright Adjusts Deciphera Pharmaceuticals' Price Target to $25 from $20, Reiterat..
MT
09/12Deciphera Pharmaceuticals, Inc. : Regulation FD Disclosure, Financial Statements and Exhib..
AQ
09/11Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT..
BU
09/11Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT..
CI
09/10Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation D..
BU
09/10Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation D..
CI
09/01Deciphera Pharmaceuticals, Inc. to Host Virtual Investor Event Featuring Key Opinion Le..
BU
More news
Analyst Recommendations on DECIPHERA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 130 M - -
Net income 2022 -178 M - -
Net cash 2022 190 M - -
P/E ratio 2022 -7,48x
Yield 2022 -
Capitalization 1 266 M 1 266 M -
EV / Sales 2022 8,29x
EV / Sales 2023 6,83x
Nbr of Employees 280
Free-Float 72,4%
Chart DECIPHERA PHARMACEUTICALS, INC.
Duration : Period :
Deciphera Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DECIPHERA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 18,94 $
Average target price 18,78 $
Spread / Average Target -0,86%
EPS Revisions
Managers and Directors
Steven L. Hoerter President & Chief Executive Officer
Thomas P. Kelly Chief Financial Officer, Treasurer & Executive VP
James A. Bristol Chairman
Daniel L. Flynn President, Chief Executive Officer & Director
Stephen B. Ruddy Chief Technical Officer & SVP
Sector and Competitors
1st jan.Capi. (M$)
DECIPHERA PHARMACEUTICALS, INC.94.88%1 266
REGENERON PHARMACEUTICALS, INC.18.08%79 063
VERTEX PHARMACEUTICALS37.53%77 102
BIONTECH SE-46.64%33 432
WUXI APPTEC CO., LTD.-39.54%29 067
GENMAB A/S0.76%23 187